These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31681614)

  • 1. Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift.
    Chawla A; Ferrone CR
    Front Oncol; 2019; 9():1085. PubMed ID: 31681614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
    Janssen QP; O'Reilly EM; van Eijck CHJ; Groot Koerkamp B
    Front Oncol; 2020; 10():41. PubMed ID: 32083002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC).
    Seufferlein T; Ettrich TJ
    Transl Gastroenterol Hepatol; 2019; 4():21. PubMed ID: 30976724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.
    Taboada AGM; Lominchar PL; Roman LM; García-Alfonso P; Martin AJM; Rodriguez JAB; Pascual JMA
    Ann Hepatobiliary Pancreat Surg; 2021 May; 25(2):179-191. PubMed ID: 34053920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer.
    Scheufele F; Hartmann D; Friess H
    Transl Gastroenterol Hepatol; 2019; 4():32. PubMed ID: 31231699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
    Schwarz L; Vernerey D; Bachet JB; Tuech JJ; Portales F; Michel P; Cunha AS
    BMC Cancer; 2018 Jul; 18(1):762. PubMed ID: 30041614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant therapy in resectable pancreatic cancer-is this the way forward?-a narrative review.
    Perri G; Marchegiani G; Malleo G; Salvia R
    Chin Clin Oncol; 2021 Jan; 10(5):47. PubMed ID: 34378394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Treatment in Pancreatic Cancer.
    Oba A; Ho F; Bao QR; Al-Musawi MH; Schulick RD; Del Chiaro M
    Front Oncol; 2020; 10():245. PubMed ID: 32185128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery for Pancreatic Cancer after neoadjuvant treatment.
    Hackert T
    Ann Gastroenterol Surg; 2018 Nov; 2(6):413-418. PubMed ID: 30460344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer.
    Klaiber U; Leonhardt CS; Strobel O; Tjaden C; Hackert T; Neoptolemos JP
    Langenbecks Arch Surg; 2018 Dec; 403(8):917-932. PubMed ID: 30397779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Sulciner ML; Ashley SW; Molina G
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma.
    Blair AB; Sorber R; Rozich NS; Burkhart RA
    Pancreas; 2019 Sep; 48(8):973-984. PubMed ID: 31425483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Trinh KV; Fischer DA; Gardner TB; Smith KD
    Front Oncol; 2020; 10():1461. PubMed ID: 33042792
    [No Abstract]   [Full Text] [Related]  

  • 17. Neoadjuvant therapy in pancreatic cancer: an emerging strategy.
    Bittoni A; Santoni M; Lanese A; Pellei C; Andrikou K; Stefano C
    Gastroenterol Res Pract; 2014; 2014():183852. PubMed ID: 25101123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.